A Hard Look: How Did China Pharma Growth Fall So Fast, So Steeply?
This article was originally published in PharmAsia News
While many are still shocked by the double-digit drop in quarterly pharma sales in the world’s second-largest economy, the underlying factors for the fast deterioration in China have in fact been brewing for some time and are multi-faceted, Yang Dongsheng of the R&D based Pharmaceutical Association Committee (RDPAC) tells PharmAsia News in an exclusive interview.
You may also be interested in...
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.
The move may signal China is accelerating the vaccine to hit the general market soon, but a false impression of the vaccine’s safety may be potentially misleading, says one regulatory expert.